Innoviva, Inc.
Innoviva, Inc. (INVA) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Innoviva, Inc. (INVA), covering cash flow, earnings, and balance sheets.
Innoviva, Inc. (INVA) Income Statement & Financial Overview
View the income breakdown for Innoviva, Inc. INVA across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $88.63M | $91.81M | $89.51M | $103.35M |
| Cost of Revenue | $8.84M | $7.17M | $9.99M | $18.39M |
| Gross Profit | $79.79M | $78.08M | $79.52M | $84.97M |
| Gross Profit Ratio | $0.90 | $0.85 | $0.89 | $0.82 |
| R&D Expenses | $4.40M | $3.67M | $3.55M | $2.56M |
| SG&A Expenses | $27.49M | $31.33M | $26.22M | $27.72M |
| Operating Expenses | $121.22M | $41.50M | $29.77M | $30.28M |
| Total Costs & Expenses | $130.06M | $48.67M | $39.76M | $48.67M |
| Interest Income | $4.54M | $5.77M | $5.50M | $3.47M |
| Interest Expense | $4.71M | $4.75M | $5.81M | $5.80M |
| Depreciation & Amortization | $6.47M | $6.51M | $6.51M | $9.92M |
| EBITDA | -$27.40M | $35.95M | $19.17M | -$23.56M |
| EBITDA Ratio | -$0.31 | $0.39 | $0.21 | -$0.23 |
| Operating Income | -$41.43M | $43.14M | $49.75M | $54.69M |
| Operating Income Ratio | -$0.47 | $0.47 | $0.56 | $0.53 |
| Other Income/Expenses (Net) | $2.84M | -$18.45M | -$42.90M | -$93.97M |
| Income Before Tax | -$38.59M | $24.69M | $6.85M | -$39.28M |
| Income Before Tax Ratio | -$0.44 | $0.27 | $0.08 | -$0.38 |
| Income Tax Expense | $8.00M | $4.36M | $5.64M | -$4.59M |
| Net Income | -$46.58M | $20.33M | $1.21M | -$34.69M |
| Net Income Ratio | -$0.53 | $0.22 | $0.01 | -$0.34 |
| EPS | -$0.74 | $0.32 | $0.02 | -$0.55 |
| Diluted EPS | -$0.74 | $0.24 | $0.02 | -$0.55 |
| Weighted Avg Shares Outstanding | $62.71M | $62.73M | $62.57M | $62.53M |
| Weighted Avg Shares Outstanding (Diluted) | $62.71M | $84.20M | $62.95M | $62.53M |
Over the past four quarters, Innoviva, Inc. demonstrated steady revenue growth, increasing from $103.35M in Q2 2024 to $88.63M in Q1 2025. Operating income reached -$41.43M in Q1 2025, maintaining a consistent -47% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$27.40M, reflecting operational efficiency. Net income dropped to -$46.58M, with EPS at -$0.74. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan